Metastatic Leiomyosarcoma Clinical Trial
Official title:
A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy
This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving chemotherapy with a gemcitabine-based regimen.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03670069 -
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
|
Phase 1 | |
| Terminated |
NCT03074318 -
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT02601209 -
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05633381 -
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04200443 -
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
| Withdrawn |
NCT05174455 -
Niraparib for the Treatment of Leiomyosarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT02428192 -
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
|
Phase 2 |